Shining a light on cancer

We are developing a multi-cancer platform powered by our Dxcover AI Engine, with first application in earlier diagnosis of brain tumours.

The Dxcover Platform has been developed to enable earlier detection of cancer.

 
Chroma-Background_02.jpg

OUR MISSION

To be a world leader in liquid biopsy and artificial intelligence for early detection  of cancers and other diseases to improve survival and quality of life.

From the Newsroom

90%

 OF PATIENTS SURVIVE WHEN CANCER IS FOUND EARLY. EARLY DIAGNOSIS BEATS CANCER.  

Reference - CRUK Statistics impact of early diagnosis

18/06/21

ClinSpec Diagnostics rebrands as Dxcover and targets growth

Dxcover Limited is the new name for the cancer diagnostics company formerly known as ClinSpec Diagnostics. ClinSpec Diagnostics, the...

04/03/21

Cancer diagnostics firm completes £3.5M funding round

ClinSpec Diagnostics Limited (ClinSpec Dx), the Glasgow-based developer of liquid biopsies for early detection of cancer, has reached its...

07/09/20

ClinSpec Dx receive £2.4m funding boost

Efforts to improve the early detection of cancer have received a significant boost with a £2.4 million funding deal to support the...